EUVIMEDEUVIMED entdecken
Crossref

Heparin-induced Thrombocytopenia with Thrombosis in COVID-19 versus Vaccine-induced Immune Thrombocytopenia and Thrombosis in the United Kingdom

Deepa J Arachchillage, Indika Rajakaruna, Mike Makris, Mike Laffan, CA-COVID-19 Investigators

Seminars in Thrombosis and Hemostasis · 01.10.2024 · 50 (07) · 1022-1025

DOI: 10.1055/s-0044-1785484 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Seminars in Thrombosis and Hemostasis, erschienen am 01.10.2024. Verfasst von Deepa J Arachchillage und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom. Hauptthemen laut MEDLINE: Heparin, COVID-19, Thrombosis, Thrombocytopenia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heparin-induced thrombocytopenia (HIT) with thrombosis (HITT) is a clinicopathological syndrome caused by IgG antibodies binding to heparin-platelet factor 4 (PF4), creating an immune complex which activates platelets and produces a hypercoagulable state. This results in thrombocytopenia and thrombosis, arising usually 5 to 10 days (range 4–15 days) following heparin exposure.[ 1 ] Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare prothrombotic syndrome associated with adenoviral vector-based ChAdOx1 CoV-19 vaccine (AstraZeneca, University of Oxford) or Ad26.COV2.S vaccine (Janssen; Johnson & Johnson).[ 2 ] VITT is characterized by thrombocytopenia and thrombosis, often at unusual sites such as cerebral venous sinus thrombosis (CVST), with the development of IgG antibodies which also bind to PF4 but without dependence on heparin or previous heparin exposure.[ 2 ] The full extent of the similarity and difference between these two related syndromes has not been fully described. We therefore, compared the incidences, characteristics, and clinical outcomes of HIT in patients with coronavirus disease 2019 (COVID-19), exposed to heparin from a multicenter observational study (coagulopathy associated with COVID-19 [CA-COVID-19]; https://www.clinicaltrials.gov/ct2/show/NCT04405232 ) with those published for VITT following ChAdOx1 CoV-19 vaccination in the United Kingdom,[ 3 ] and also HIT in patients admitted to hospitals without COVID-19.[ 4 ] Of 5,971 patients with COVID-19 admitted to 30 National Health Service (NHS) Trusts across the United Kingdom from the first wave of the COVID-19 pandemic (between April 1, 2020, and July 31, 2020), 26 patients developed HIT at a median 13 (6–27) days following exposure to heparin, making an incidence of 0.43%. Of these 26 patients, 25 (96%) developed HITT (i.e., HIT with associated thrombosis). The median age of the patients who developed HITT was 47 (range 35–73) years. The reported incidence of HIT in the United States is approximately 1 in 1,500 hospital admissions (0.067%).[ 4 ] Patients undergoing cardiopulmonary bypass had the highest rates of HIT followed by patients on hemodialysis, while patients who undertook hip and knee arthroplasty had the lowest rates of HIT.[ 4 ] In general, it appears that lower frequencies are seen with low-molecular weight heparin (LMWH) versus unfractionated heparin (UFH), prophylactic versus therapeutic doses, medical versus surgical patients, and minor versus major trauma.[ 5 ] [ 6 ] Although there are no nationwide studies assessing the incidence of HIT in patients admitted to hospitals in the United Kingdom, we anticipate that it is similar to that of the published U.S. study.[ 4 ] Although several factors have been reported to affect the incidence of HIT including, as stated in the prior cited studies,[ 4 ] [ 5 ] [ 6 ] such as type of heparin (LMWH vs. UFH), prophylactic versus treatment dose heparin, duration of heparin exposure, type of patients studied (medical vs. surgical) and type of surgery, findings are not necessarily consistent between studies. Furthermore, the number of patients included in published studies vary and most include only small numbers of patients. Based on the data reported by May 12, 2021, the estimated incidence of VITT was approximately 7 to 10 cases per million persons receiving ChAdOx1 CoV-19 vaccine (309 VITT cases were reported from the 32.9 million doses given in the United Kingdom) and approximately 3.2 cases per million for the Ad26.COV2.S (or 28 cases out of 8.7 million doses administered in the United States).[ 7 ] The incidence of VITT varied according to age and was at least 1:100,000 and 1:50,000 among patients ≥50 or

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HeparinCOVID-19ThrombosisThrombocytopeniaCOVID-19 VaccinesSARS-CoV-2HumansUnited KingdomFemalePurpura, Thrombocytopenic, IdiopathicMaleAnticoagulants

Substanzen

HeparinCOVID-19 VaccinesAnticoagulants

Autor:innen und Institutionen

  • Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.
  • Department of Haematology, Imperial College, Healthcare NHS Trust, London, United Kingdom.
  • Department of Computer Science, University of East London, London, United Kingdom.
  • School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom.

Zitieren

APA

Arachchillage, D. J., Rajakaruna, I., Makris, M., Laffan, M., & CA-COVID-19 Investigators (2024). Heparin-induced Thrombocytopenia with Thrombosis in COVID-19 versus Vaccine-induced Immune Thrombocytopenia and Thrombosis in the United Kingdom. Seminars in Thrombosis and Hemostasis, 50(07), 1022-1025. https://doi.org/10.1055/s-0044-1785484

Vancouver

Arachchillage DJ, Rajakaruna I, Makris M, Laffan M, CA-COVID-19 Investigators. Heparin-induced Thrombocytopenia with Thrombosis in COVID-19 versus Vaccine-induced Immune Thrombocytopenia and Thrombosis in the United Kingdom. Seminars in Thrombosis and Hemostasis. 2024;50(07):1022-1025. doi:10.1055/s-0044-1785484

BibTeX
@article{Arachchillage2024,
  author = {Arachchillage, Deepa J and Rajakaruna, Indika and Makris, Mike and Laffan, Mike and CA-COVID-19 Investigators, CA-COVID-19 Investigators},
  title = {Heparin-induced Thrombocytopenia with Thrombosis in COVID-19 versus Vaccine-induced Immune Thrombocytopenia and Thrombosis in the United Kingdom},
  journal = {Seminars in Thrombosis and Hemostasis},
  year = {2024},
  volume = {50},
  number = {07},
  pages = {1022--1025},
  doi = {10.1055/s-0044-1785484}
}
Kostenlos starten →